Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.59 USD
Change Today +0.0499 / 9.24%
Volume 127.2K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

sophiris bio inc (SPHS) Snapshot

Open
$0.54
Previous Close
$0.54
Day High
$0.59
Day Low
$0.50
52 Week High
04/14/14 - $3.73
52 Week Low
02/4/15 - $0.42
Market Cap
9.9M
Average Volume 10 Days
199.8K
EPS TTM
$-1.85
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOPHIRIS BIO INC (SPHS)

Related News

No related news articles were found.

sophiris bio inc (SPHS) Related Businessweek News

No Related Businessweek News Found

sophiris bio inc (SPHS) Details

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of products for the treatment of urological diseases. Its primary product candidate includes PRX302, which is in Phase III clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of prostate cancer. Sophiris Bio, Inc. has a strategic relationship with Kissei Pharmaceutical Co., Ltd. or the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. is based in La Jolla, California.

9 Employees
Last Reported Date: 03/10/15

sophiris bio inc (SPHS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $437.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $293.4K
Chief Operating Officer and Head of Research ...
Total Annual Compensation: $339.9K
Compensation as of Fiscal Year 2013.

sophiris bio inc (SPHS) Key Developments

Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Sophiris Bio, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net loss before income taxes of $5,280,000 against $5,438,000 a year ago. Net loss was $5,280,000 or $0.31 per basic and diluted share against $5,438,000 or $0.34 per basic and diluted share a year ago. For the year, the company reported net loss before income taxes of $30,712,000 against $10,649,000 a year ago. Net loss was $30,712,000 or $1.85 per basic and diluted share against $11,149,000 or $1.39 per basic and diluted share a year ago.

Sophiris Bio Receives Non-Compliance Notice From NASDAQ

On January 29, 2015, Sophiris Bio Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq) notifying the Company that the consolidated closing bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Marketplace Rule 5450(a)(1). The notification from Nasdaq does not have an immediate effect on the listing of the Company’s common stock and the Company’s common stock will continue to trade on The Nasdaq Global Market under the symbol "SPHS". Nasdaq stated in its January 29th letter that, in accordance with Marketplace Rule 5810(c)(3)(A), the Company has been provided a grace period of 180 calendar days, or until July 28, 2015, to regain compliance with the minimum consolidated closing bid price requirement for continued listing. Compliance will be regained if the Company’s consolidated closing bid price is at or above $1.00 for at least 10 consecutive trading days anytime during the 180-day grace period. The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

Sophiris Bio, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 11:05 AM

Sophiris Bio, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 11:05 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Randall E. Woods, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPHS:US $0.59 USD +0.0499

SPHS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPHS.
View Industry Companies
 

Industry Analysis

SPHS

Industry Average

Valuation SPHS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOPHIRIS BIO INC, please visit www.sophirisbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.